Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome.
Sjogren’s syndrome
comorbidities
concomitant medications
depression
fatigue
pain
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
12
2018
revised:
20
03
2019
accepted:
27
03
2019
entrez:
7
6
2019
pubmed:
7
6
2019
medline:
7
6
2019
Statut:
epublish
Résumé
To report on fatigue in patients from the United Kingdom primary Sjögren's syndrome (pSS) registry identifying factors associated with fatigue and robust to assignable causes such as comorbidities and medications associated with drowsiness. From our cohort (n = 608), we identified those with comorbidities associated with fatigue, and those taking medications associated with drowsiness. We constructed dummy variables, permitting the contribution of these potentially assignable causes of fatigue to be assessed. Using multiple regression analysis, we modelled the relationship between Profile of Fatigue and Discomfort physical and mental fatigue scores and potentially related variables. Pain, depression and daytime sleepiness scores were closely associated with both physical and mental fatigue (all p ≤ 0.0001). In addition, dryness was strongly associated with physical fatigue (p ≤ 0.0001). These effects were observed even after adjustment for comorbidities associated with fatigue or medications associated with drowsiness. These findings support further research and clinical interventions targeting pain, dryness, depression and sleep to improve fatigue in patients with pSS.This finding is robust to both the effect of other comorbidities associated with fatigue and medications associated with drowsiness.
Identifiants
pubmed: 31168409
doi: 10.1136/rmdopen-2018-000885
pii: rmdopen-2018-000885
pmc: PMC6525628
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e000885Subventions
Organisme : Versus Arthritis
ID : 22026
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0800629
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J002720/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003063/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
Competing interests: SJB has provided consultancy services in the area of Sjögren’s syndrome for the following companies: Celgene, Eli Lilly, Glenmark, GSK, Medimmune, Novartis, Ono, Pfizer, Takeda, UCB. PE has undertaken clinical trials and provided expert advice to Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Lilly. WFN has undertaken clinical trials and provided consultancy or expert advice in the area of Sjögren’s syndrome to the following companies: GlaxoSmithKline, MedImmune, Novartis, UCB, Abbvie, Roche, Eli Lilly, Takeda, Resolves Therapeutics, and Nascient.
Références
Ann Rheum Dis. 2014 Jul;73(7):1362-8
pubmed: 23761688
Health Qual Life Outcomes. 2009 May 27;7:46
pubmed: 19473510
Sleep Med Rev. 2006 Feb;10(1):63-76
pubmed: 16376590
Arthritis Care Res (Hoboken). 2012 Nov;64(11):1760-4
pubmed: 23111856
Reumatismo. 2014 Jun 06;66(1):39-43
pubmed: 24938195
PLoS One. 2017 Oct 31;12(10):e0187272
pubmed: 29088284
Ann Rheum Dis. 2015 May;74(5):859-66
pubmed: 24442883
Arthritis Rheum. 2008 Dec 15;59(12):1780-7
pubmed: 19035421
Occup Med (Lond). 2010 Mar;60(2):159
pubmed: 20157190
Arthritis Care Res (Hoboken). 2013 Jun;65(6):862-9
pubmed: 23729241
Sleep Med Clin. 2014 Jun 1;9(2):261-274
pubmed: 25477769
Occup Med (Lond). 2010 Aug;60(5):326-9
pubmed: 20650864
Lupus. 2013 Oct;22(11):1118-27
pubmed: 23989737
Clin Exp Rheumatol. 2017 Mar-Apr;35(2):255-261
pubmed: 28032845
J Int Med Res. 2013 Aug;41(4):1150-9
pubmed: 23803306
J Behav Med. 2014 Aug;37(4):683-97
pubmed: 23744045
Rheumatology (Oxford). 2004 Jun;43(6):758-64
pubmed: 15039495
Rheumatology (Oxford). 2012 Feb;51(2):262-9
pubmed: 21705778
Scand J Rheumatol. 2017 Jan;46(1):49-55
pubmed: 27098775
Rheumatology (Oxford). 2010 May;49(5):844-53
pubmed: 20147445
Clin Psychol Rev. 2005 Jul;25(5):559-92
pubmed: 15970367
BMC Health Serv Res. 2003 Dec 31;3(1):25
pubmed: 14702202
Arthritis Care Res (Hoboken). 2018 Jul;70(7):1064-1073
pubmed: 29409110
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
J Clin Sleep Med. 2009 Jun 15;5(3):263-76
pubmed: 19960649
Rheumatology (Oxford). 2011 Jan;50(1):32-9
pubmed: 20693261
Rheumatology (Oxford). 2013 Dec;52(12):2136-48
pubmed: 24003249
Clin Rheumatol. 2015 Dec;34(12):2029-39
pubmed: 25620673
Rheumatology (Oxford). 2010 Jun;49(6):1177-83
pubmed: 20308122
J Nerv Ment Dis. 2008 May;196(5):429-31
pubmed: 18477888
Arthritis Care Res (Hoboken). 2013 Aug;65(8):1291-8
pubmed: 23335582
RMD Open. 2016 Jul 19;2(2):e000282
pubmed: 27493792
Rheumatology (Oxford). 2017 Oct 1;56(10):e24-e48
pubmed: 28957550
Rheumatology (Oxford). 2017 Apr 1;56(4):570-580
pubmed: 28013207
Neurosci Bull. 2007 Jul;23(4):236-40
pubmed: 17687399
Int J Crit Illn Inj Sci. 2011 Jul;1(2):104-9
pubmed: 22229132